Epilepsy Drugs Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031

Epilepsy Drugs Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment (First-Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography

  • Report Code : TIPRE00024323
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Epilepsy Drugs Market Strategies, Trends, and Forecast by 2031

Buy Now

The epilepsy drugs market size is projected to reach US$ 11.9 billion by 2031 from US$ 8.3 billion in 2023. The market is expected to register a CAGR of 4.5% during 2023–2031. Rising Research & Development (R&D) activities are likely to remain key trends in the market.

Epilepsy Drugs Market Analysis

Rising clinial trials for epilepsy drugs to develop innovative drugs will provide lucrative opportunity for the market growth in the coming years. For example, Mayo Clinic conducted clinical trial to investigate the effectiveness and safety of "Fenfluramine Hydrochloride Oral Solution (ZX008) as an Adjuvant Therapy for children with Intractable Epilepsy with Myoclonic-Atonic Seizures. Further, rising incidence of epilepsy cases accelerate demand for antiepileptic drugs will drive market growth. For example, companies launching innovative products by the company is an influential factor responsible to account considerable market growth during 2021-2031. Rising Research & Development (R&D) activities are likely to remain key trends in the market.

Epilepsy Drugs Market Overview

According to the WHO report, globally, an estimated 5 million people are diagnosed with epilepsy annually. For records, in high-income countries, there are an estimated 49 per 100000 people diagnosed with epilepsy, and in low-income countries, this figure is as high as 139 per 100000. The World Health Organization (WHO) report further reveals that epilepsy accounts for more than 0.5% of the global burden of disease, with out-of-pocket costs creating a substantial burden on households. Therefore, rising cases of epilepsy will accelerate demand for antiepileptic drugs in the coming decade.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Epilepsy Drugs Market: Strategic Insights

Epilepsy Drugs Market

  • CAGR (2023 - 2031)
    4.5%
  • Market Size 2023
    US$ 8.3 Billion
  • Market Size 2031
    US$ 11.9 Billion

Market Dynamics

GROWTH DRIVERS
  • Rising Incidence of Epilepsy Cases Accelerate Demand for Antiepileptic Drugs to Favor Market
FUTURE TRENDS
  • Rising Research & Development (R&D) activities are likely to remain key trends in the market
OPPORTUNITIES
  • Rising Clinical Trials for Epilepsy Drugs Provide Lucrative Market Opportunity

Key Players

  • UCB SA,
  • Novartis AG,
  • Pfizer,
  • GSK,
  • Abbott,
  • Sanofi,
  • Sumito Pharma Company,
  • Teva Pharmaceuticals,
  • Catalyst Pharmaceuticals,
  • Alkem Laboratories,

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Treatment
  • First-Generation Anti-Epileptics
  • Second Generation Anti-Epileptics
  • Third Generation Anti-Epileptics
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Epilepsy Drugs Market Drivers and Opportunities

Rising Incidence of Epilepsy Cases Accelerate Demand for Antiepileptic Drugs to Favor Market

According to the WHO 2024 published report, around 50 million people globally have epilepsy, making it the most common neurological disease—the rising incidence of epilepsy results in a considerable burden of healthcare costs worldwide. For example, it has been estimated that the 6 million people with active epilepsy cost over US$21.5 billion annually, and despite this, very few European countries have national plans to manage epilepsy disorder. Therefore, demand for antiepileptic drugs is high in demand to prevent seizures. For example, upto 70% of people living with epilepsy could become seizure free with appropiate use of antiseizures medicines as per the WHO report. Furthermore, rising prevalence of epilepsy cases accelerate demand for antiepileptic drugs are the major drivers of global epilepsy drugs market share.

Rising Clinical Trials for Epilepsy Drugs Provide Lucrative Market Opportunity

For example, Équilibre Biopharmaceuticals’s "EQU-001" witness "Phase Transition Success Rate (PTSR)" as the company reported Phase 2 results for anti-epileptic drugs. Additionally, the SANAD clinical trial was design to identofy the most effective and cost-effective treatments for patients with epilepsy. Previosuly "Valproate" was approved to control the seizures and was more efficacious over "Lamotrigine" and was the first drug choice for many patients suffering from generalized and unclassified epilepsies. However, due to adverse effects of valproate during pregnancy the physicians stop prescribing the drug. Further, the Lamotrigine through clinical trials was clinially proven better than valproate with cost effective alternative for patients diagnosed with partial onset seizures. Further, in 2024, the results from the clinical trial SANAD-2 are yet to be announced for new antiepileptic drugs. Therefore, rising clinical trials for development of new antiepileptic drugs is seen to leave a positive impact on the market, as it has an opportunity for innovative drugs.

Epilepsy Drugs Market Report Segmentation Analysis

Key segments that contributed to the derivation of the epilepsy drugs market analysis are type, cause, disorder type, category, and end user.

  • Based on treatment, the epilepsy drugs market is segmented as first-generation anti-epileptics, second generation anti-epileptics, third generation anti-epileptics. The second generation anti-epileptics segment held the largest market share in 2023.
  • By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2023.

Epilepsy Drugs Market Share Analysis by Geography

The geographic scope of the Epilepsy Drugs market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the market. In North America region, the US accounts largest share for epilepsy drugs market. Presence of top manufacturers in the region and their innovative antiepileptic drugs having effective pharmacological activity are the factors contributing to the dominance of the market. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.  

Epilepsy Drugs Market Report Scope

Report Attribute Details
Market size in 2023 US$ 8.3 Billion
Market Size by 2031 US$ 11.9 Billion
Global CAGR (2023 - 2031) 4.5%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Treatment
  • First-Generation Anti-Epileptics
  • Second Generation Anti-Epileptics
  • Third Generation Anti-Epileptics
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • UCB SA,
  • Novartis AG,
  • Pfizer,
  • GSK,
  • Abbott,
  • Sanofi,
  • Sumito Pharma Company,
  • Teva Pharmaceuticals,
  • Catalyst Pharmaceuticals,
  • Alkem Laboratories,
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

    Epilepsy Drugs Market News and Recent Developments

    The Epilepsy Drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Epilepsy Drugs market are listed below:

    • Eisai Co., Ltd. announced new product launch "Fycompa" intended for intravenous (IV) infusion. The injection formulation of Fycompa received manufacturing and marketing approval on January 2024 and this was included in the Japan's National Health Insurance (NHI) Drug Price list today. Fycompa is the first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. (Source: Eisai Co., Ltd, Press Release, April 2024)

    Epilepsy Drugs Market Report Coverage and Deliverables

    The “Epilepsy Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Epilepsy Drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Epilepsy Drugs market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Epilepsy Drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Epilepsy Drugs market
    • Detailed company profiles
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    Treatment, Distribution Channel, and Geography

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    Which region dominated the epilepsy drugs market in 2023?

    North America region dominated the epilepsy drugs market in 2023.

    What are the driving factors impacting the epilepsy drugs market?

    Rising incidence of epilepsy cases accelerate demand for antiepileptic drugs is one of the most influential factors responsible for market growth.

    What are the future trends of the epilepsy drugs market?

    Rising Research & Development (R&D) activities to remain as a key trend for epilepsy drugs market.

    Which are the leading players operating in the epilepsy drugs market?

    UCB SA, Novartis AG, Pfizer, GSK, Abbott, Sanofi, Sumito Pharma Company, Teva Pharmaceuticals, Catalyst Pharmaceuticals, and Alkem Laboratories are the key players in the epilepsy drugs market.

    What would be the estimated value of the epilepsy drugs market by 2031?

    The estimated value of epilepsy drugs market accounted US$ 11.9 billion in 2031.

    What is the expected CAGR of the epilepsy drugs market?

    The CAGR for epilepsy drugs accounted 4.5% during 2023-2031.

    Trends and growth analysis reports related to Pharmaceuticals : READ MORE..